Truist cuts Progyny stock price target on covered lives miss
#Progyny #Truist Securities #Price target #Covered lives #NASDAQ:PGNY #Stock analysis #Healthcare benefits #Fertility services
📌 Key Takeaways
- Truist cut Progyny's price target to $28 from $34 while maintaining a Buy rating
- Progyny's 2026 covered lives outlook missed expectations by 400,000 people
- The company's stock dropped over 20% following the announcement
- Technical indicators suggest the stock may be undervalued despite the recent decline
📖 Full Retelling
Truist Securities lowered its price target on Progyny shares (NASDAQ:PGNY) to $28 from $34 while maintaining a Buy rating on the stock on February 3, 2026, after the fertility benefits provider's 2026 covered lives outlook came in 400,000 below expectations set during its third-quarter call. The company also issued 2026 EBITDA guidance slightly below consensus, contributing to the analyst's decision to revise their outlook. The shortfall in covered lives raised investor concerns about broader layoffs and employer demand trends potentially affecting the company's growth trajectory. Progyny provides fertility and family building benefits management services to employers across the United States. The stock's significant drop comes despite the company having previously reported strong financial results for the fourth quarter of 2025, with earnings per share of $0.48 significantly exceeding analysts' expectations of $0.14, and revenue of $318.4 million surpassing the projected $306.06 million.
🏷️ Themes
Stock Market, Healthcare, Financial Analysis
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Gold prices soar as Middle East conflict spurs safe haven demand Oil prices surge after U.S.-Israel strikes on Iran; crude around $80/bbl likely Dollar surges on Middle East conflict; euro, sterling retreat Futures drop, oil spikes amid widening Mideast conflict - what’s moving markets FLASH SALE (South Africa Philippines Nigeria) FLASH SALE Truist cuts Progyny stock price target on covered lives miss By Investing.com Analyst Ratings Published 03/02/2026, 06:17 AM Truist cuts Progyny stock price target on covered lives miss 0 PGNY -20.49% Investing.com - Truist Securities lowered its price target on Progyny shares (NASDAQ:PGNY) to $28 from $34 while maintaining a Buy rating on the stock. The firm reduced its target after Progyny ’s 2026 covered lives outlook came in 400,000 below expectations set during its third-quarter call. The company also issued 2026 EBITDA guidance slightly below consensus. Progyny shares fell more than 20% on Friday following the announcement, dropping from $22.25 to $17.69 and trading near its 52-week low of $16.75. According to InvestingPro data, the stock’s RSI suggests it is in oversold territory, with the company’s Fair Value indicating the shares may be undervalued at current levels. The shortfall in covered lives raised investor concerns about broader layoffs and employer demand trends potentially affecting the company’s growth trajectory. For deeper insights into PGNY’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, available for this and 1,400+ other US equities on InvestingPro . Truist Securities noted that a modest miss on 2026 adjusted EBITDA guidance likely was not a major surprise based on investor conversations before and after the results. The firm said it caught up with Progyny for further clarification on the guidance. Progyny provides fertility and family building benefits management services to employers. In other ...
Read full article at source